How the Adolescent COVID Vaccine Market Could Be Huge for Pfizer... Eventually
Until recently, children under age 16 couldn't receive a COVID-19 vaccine. That changed, though, with Pfizer (NYSE: PFE) and BioNTech (NASDAQ: BNTX) receiving U.S. Emergency Use Authorization (EUA) for their vaccine in adolescents between the ages of 12 and 15. In this Motley Fool Live video recorded on May 17, healthcare and cannabis bureau chief Corinne Cardina and Motley Fool contributor Keith Speights discuss how big the adolescent vaccine market might be for Pfizer.
Source Fool.com
